Pfizer puts up $1bn to buy into Arvinas breast cancer programme
pharmaphorum
JULY 22, 2021
The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for HER2 receptors that would make them candidates for treatment with drugs like trastuzumab. billion in backloaded milestone payments.
Let's personalize your content